Overview

A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX

Status:
Unknown status

Trial end date:
2018-04-01

Target enrollment:

Participant gender:

Summary

A multicenter, randomized, parallel assignment, double blind, placebo-controlled, safety/efficacy phase II study of two different dosages of subcutaneous F8IL10 in patients with active rheumatoid arthritis receiving MTX.

Phase:

Phase 2

Details

Lead Sponsor:

Philogen S.p.A.

Treatments:

Methotrexate